drugset / Trial / NCT00655356

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

NCT00655356 ↗

Phase 3 Completed 218 enrolled Castle Creek Biosciences, LLC.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.

Timeline

Start
2006-11
Primary completion
2008-07
Completion
2009-05

Outcome

Met primary endpoint

registry NUMBER Autologous Fibroblasts: 50 participants NUMBER Placebo: 19 participants analysis (superiority or other test); Autologous Fibroblasts vs Placebo; p <.00001 NCT00655356 ↗

registry NUMBER Autologous Fibroblasts: 21 participants NUMBER Placebo: 8 participants analysis (superiority or other test); Autologous Fibroblasts vs Placebo; p = .0075 NCT00655356 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject azficel-T Cell therapy — Other

Indications

No indication recorded.